Introduction
============

Psychostimulants, such as amphetamine derivates, methylphenidate, and modafinil, as well as the nonstimulant medication atomoxetine, are considered first-line medication treatment of attention deficit hyperactivity disorder (ADHD) symptoms in the pediatric population.[@b1-ndt-7-729] Case reports on serious cardiovascular adverse drug reactions (ADRs), sudden death, and psychiatric disorders led regulatory agencies to warn against the use of methylphenidate in the pediatric population in 2006 and 2007.[@b2-ndt-7-729],[@b3-ndt-7-729] In 2006, warnings were also linked to atomoxetine use due to reports of hepatotoxicity and suicidal thoughts in children.[@b4-ndt-7-729] Concern has been raised about ADRs from long-term treatment with ADHD medications, such as psychosis, sensitization, dependency, and withdrawal reactions.[@b1-ndt-7-729] The issue of appropriate warnings about possible ADRs to the use of methylphenidate and other ADHD medications is ever more important as usage continues to increase rapidly in many countries: an increase in the number of treated patients has been observed, as well as an increase in the average dispensed daily dose of psychostimulants.[@b5-ndt-7-729]

The use of psychostimulants, particularly methylphenidate, to treat ADHD symptoms in children has increased rapidly since the 1990s. Studies have shown that the prevalence of psychostimulant use in children in the Netherlands increased eight times from 1996 to 2006,[@b6-ndt-7-729] and in Germany, prescription rates of methylphenidate increased by 96% from 2000 to 2007.[@b7-ndt-7-729] From 1994 to 2004, the prevalence of psychostimulant use in Norwegian children increased five times,[@b8-ndt-7-729] while the prevalence of stimulant medication increased ten times in American children from 1987 to 1996.[@b9-ndt-7-729] Previous meta-analyses and reviews that evaluated the short-term efficacy of psychostimulants on ADHD symptoms in children concluded that psychostimulants are more effective than placebo with respect to treating disturbed attention and impulsivity.[@b1-ndt-7-729],[@b10-ndt-7-729] Several articles have reported information about the safety of methylphenidate and other psycho-stimulants in clinical studies,[@b11-ndt-7-729] but to the current reviewers' knowledge no articles have systematically reviewed the occurrence of ADRs following the use of ADHD medications in the pediatric population.

The objective of this study is to review published empirical studies on the occurrence of adverse drug reactions (ADRs) associated with the use of medications generally licensed for treatment of ADHD symptoms in the pediatric population.

Methods
=======

Literature search
-----------------

A literature search was performed in PubMed, Embase, and PsycINFO^®^ (whole databases without language restriction) using the search terms "atomoxetine" (ATC group N06BA09), "methylphenidate" (ATC group N06BA04), "modafinil" (ATC group N06BA07), "amphetamine" (ATC group N06BA02), "psychostimulants," and "nonstimulants" combined with any of the following: "adverse drug reaction," "side effect," and "adverse event." Reference lists of identified articles were also screened for additional potentially relevant articles. For further details of the search strategy, please see [Appendix 1](#app1-ndt-7-729){ref-type="app"}. Literature searches were updated until September 2011.

Study selection
---------------

Using article titles as the selection basis, the first author retrieved and screened the abstracts to identify studies relevant to the study objective. Potentially relevant articles were retrieved in full text and screened for inclusion. To be considered relevant for this review, articles had to be peer reviewed and report ADRs in children in the age group 0--17 years of age associated with the use of psychostimulants.

Psychostimulants were specified as amphetamine derivates, methylphenidate, and modafinil, and nonstimulants as atomoxetine. Articles reporting ADRs from psychostimulants in mixed populations of children and adults were excluded if age-related ADR occurrence was not specified. Articles were excluded if they did not report data on ADR occurrence that made it possible to calculate rates. Hence, case reports, letters, commentaries, interim analyses, meta-analyses, and review articles were excluded. Further, articles reporting unintended events not classified as ADRs and articles on misuse were excluded, although reference lists of these studies were searched for relevant studies.

Data extraction
---------------

Data from included articles were extracted using a standard form, one for each article. The following information was recorded: authors, publication year, country, study design, dosage, comparator, monitoring period (weeks), size of study population, age and gender of included population, and ADR reporting rates in percentage. ADR reporting rates were indicated as reported in the original papers. In placebo-controlled studies, information about ADR reporting rates for placebo was also extracted. Information about who had assessed the ADRs, reported ADRs classified as being serious by the respective authors, and funding sources were also recorded. The first author extracted data, while the second author controlled and verified all cases.

Results
-------

A total of 137 potentially relevant references were identified during the database searches and reference screenings. An overview of the review process and reasons for exclusion are displayed in [Figure 1](#f1-ndt-7-729){ref-type="fig"}. Sixty-eight studies were excluded after screening abstracts. Sixty-nine studies were retrieved for full text review. Of these studies, four were later excluded as they reported mixed data on children and adults that could not be separated. Eight meta-analyses and four reviews of efficacy were excluded as they reported information from studies already included. Also excluded were two studies reporting data from a subgroup analysis of already included studies, and nine studies reporting ADRs as percent of children reporting an ADR.

Eventually 43 articles reporting ADRs from psycho-stimulants in the pediatric population were included. [Table 1](#t1-ndt-7-729){ref-type="table"} displays an overview of the study characteristics of included articles. The majority of studies were conducted in the United States of America (USA), the remaining in Australia, Canada, Europe, Iran, and Latin America. Atomoxetine studies were published in the period from 2001 to 2009; amphetamine studies from 1997 to 2007; methylphenidate studies from 1997 to 2009; and modafinil studies from 2005 to 2009.

Design and setting
------------------

Information about ADRs was reported in clinical studies using different designs, ie, randomized parallel group studies (N = 28);[@b12-ndt-7-729]--[@b15-ndt-7-729],[@b17-ndt-7-729]--[@b19-ndt-7-729],[@b22-ndt-7-729],[@b23-ndt-7-729],[@b28-ndt-7-729],[@b31-ndt-7-729],[@b32-ndt-7-729],[@b34-ndt-7-729]--[@b36-ndt-7-729],[@b40-ndt-7-729],[@b42-ndt-7-729]--[@b47-ndt-7-729],[@b48-ndt-7-729]--[@b54-ndt-7-729] randomized crossover studies (N = 6);[@b16-ndt-7-729],[@b23-ndt-7-729],[@b25-ndt-7-729],[@b27-ndt-7-729],[@b30-ndt-7-729],[@b39-ndt-7-729] and open-label designs (N = 9).[@b20-ndt-7-729],[@b26-ndt-7-729],[@b29-ndt-7-729],[@b33-ndt-7-729],[@b37-ndt-7-729],[@b38-ndt-7-729],[@b41-ndt-7-729],[@b50-ndt-7-729] The majority of studies were conducted in naturalistic settings at home and at school (N = 38);[@b12-ndt-7-729],[@b13-ndt-7-729],[@b15-ndt-7-729]--[@b22-ndt-7-729],[@b24-ndt-7-729],[@b26-ndt-7-729],[@b28-ndt-7-729]--[@b30-ndt-7-729],[@b31-ndt-7-729]--[@b43-ndt-7-729],[@b44-ndt-7-729]--[@b54-ndt-7-729] five articles reported ADRs from children participating in laboratory school protocols,[@b14-ndt-7-729],[@b23-ndt-7-729],[@b25-ndt-7-729],[@b27-ndt-7-729],[@b30-ndt-7-729] in which classroom sessions were organized in cycles to include 12 hours of observation. This design consisted of daily schedules of alternating classroom, meals/snacks, recess, and research activities scheduled at specific times during the day. The largest number of studies (N = 21)[@b31-ndt-7-729]--[@b47-ndt-7-729] concerned atomoxetine; followed by methylphenidate (N = 14;[@b17-ndt-7-729]--[@b30-ndt-7-729] modafinil (N = 7);[@b48-ndt-7-729]--[@b54-ndt-7-729] and amphetamine (N = 5).[@b12-ndt-7-729]--[@b16-ndt-7-729]

Dosage and comparator
---------------------

The tested dosages varied from 10 to 70 mg/day in amphetamine studies; from 5 to 72 mg/day in methylphenidate studies; from 10 to 90 mg/day in atomoxetine studies; and from 100 to 425 mg/day in modafinil studies. Placebo was used as a comparator drug in the majority of studies (N = 28), while an active comparator, was administered in nine studies. Seven open-label studies did not include a control group.

Treatment period
----------------

Treatment duration varied from 1 to 32 weeks across studies. Treatment duration varied from 2 to 4 weeks in amphetamine studies; from 1 to 10 weeks in methylphenidate studies; from 3 to 32 weeks in atomoxetine studies; and from 4 to 9 weeks in modafinil studies.

Population
----------

A total of 8512 children were included in the clinical studies, of which 7244 children completed treatment: amphetamine (1076); methylphenidate (2092); atomoxetine (3127); and modafinil (949). The reasons for noncompletion were many, but lack of efficacy and the appearance of ADRs were the most common. The ages of the included children varied from 4 to 17 years (median 6--12 years), and the share of male patients in the studies varied from 0 to 100% (median 69%).

Type of assessor
----------------

Parents rated information about ADRs in 20 studies,[@b12-ndt-7-729]--[@b15-ndt-7-729],[@b19-ndt-7-729],[@b25-ndt-7-729]--[@b28-ndt-7-729], [@b32-ndt-7-729],[@b35-ndt-7-729]--[@b36-ndt-7-729],[@b40-ndt-7-729]--[@b46-ndt-7-729],[@b48-ndt-7-729],[@b50-ndt-7-729],[@b52-ndt-7-729] 54 patients in 15 studies,[@b18-ndt-7-729],[@b20-ndt-7-729]--[@b24-ndt-7-729],[@b31-ndt-7-729],[@b33-ndt-7-729]--[@b35-ndt-7-729],[@b38-ndt-7-729]--[@b39-ndt-7-729],[@b42-ndt-7-729],[@b44-ndt-7-729],[@b47-ndt-7-729] and a combination of teacher/parent (five studies),[@b16-ndt-7-729]--[@b17-ndt-7-729],[@b30-ndt-7-729],[@b48-ndt-7-729]--[@b49-ndt-7-729] and patient/parent (three studies).[@b27-ndt-7-729],[@b49-ndt-7-729],[@b51-ndt-7-729] The articles specified only limited information about applied ADR scales and the classification systems used.

Funding source
--------------

In almost all studies the funding source was the manufacturer of the respective medications, and only four studies were publicly funded. Additionally, a large number of the studies were conducted by the same groups of authors who declared conflicts of interest. The majority of the authors received contributions from the pharmaceutical companies producing the medications in return for activities, such as providing scientific advice and making oral and poster presentations at scientific meetings.

ADRs by type and occurrence
---------------------------

[Tables 2](#t2-ndt-7-729){ref-type="table"}--[5](#t5-ndt-7-729){ref-type="table"} display the ADR reporting rates listed in the included studies for each type of psychostimulant. ADRs of similar type and wording were aggregated in a common category in order to clarify data presentation. The aggregated categories were: weight changes (changes in weight, weight decreased, weight increased, decrease in weight); gastrointestinal pain (abdominal pain, upper abdominal pain, gastrointestinal pain); anxiety (anxiety, anxiousness); influenza (influenza, flu syndrome); tics (tics, motor tics, facial tics); blood pressure changes (diastolic blood pressure, changes in blood pressure); sleeping problems (awake during the night, difficulty falling asleep, sleep disturbance, delayed onset of sleep); changes in heart rate (racing heart, changes in heart rate). Thirty-one categories of ADRs were reported for amphetamine derivates ([Table 2](#t2-ndt-7-729){ref-type="table"}); 65 categories for methylphenidate formulations ([Table 3](#t3-ndt-7-729){ref-type="table"}); 55 categories for atomoxetine ([Table 4](#t4-ndt-7-729){ref-type="table"}); and 38 categories for modafinil ([Table 5](#t5-ndt-7-729){ref-type="table"}). The following ADRs were most frequently reported for all four psychostimulants: decrease in appetite, gastrointestinal pain, and headache.

ADRs by seriousness
-------------------

The majority of reported ADRs were categorized by the authors/investigators as nonserious. [Table 6](#t6-ndt-7-729){ref-type="table"} shows information about the categories of serious ADRs reported in the clinical studies. Serious cases included aggression (amphetamine, methylphenidate);[@b16-ndt-7-729] anxiety (amphetamine);[@b16-ndt-7-729] emotional disturbances (amphetamine);[@b14-ndt-7-729],[@b15-ndt-7-729] insomnia (amphetamine, modafinil);[@b13-ndt-7-729],[@b15-ndt-7-729],[@b37-ndt-7-729] and attempted suicide (amphetamine).[@b13-ndt-7-729]

Discussion
==========

This is the first study to systematically review the empirical literature on the occurrence of ADRs reported for ADHD medications in the pediatric population. Information about ADRs from psychostimulants and the nonstimulant atomoxetine was reported in clinical studies of short duration, primarily conducted in 6- to 12-year-old boys, and particularly in the USA. The most frequently reported ADRs were decrease in appetite, gastrointestinal pain, and headache. A large number of studies were conducted by the same groups of authors and sponsored by the pharmaceutical companies manufacturing the respective medications.

Design and setting
------------------

Although the review process found a large number of small clinical trials exploring the efficacy of ADHD medications in the pediatic population, only a minor share of these studies reported information about ADRs. The studies included in this article were similar in design and setting, treatment duration, as well as number, age, and gender of included patients. The reliability of the studies may be questioned as the number of reported ADRs varied widely for identical and similar study designs. Further exploration of these questions would require access to the original study material. Large variations in ADR reporting rates were observed between studies and therapeutic groups, and similar types of ADRs were reported for the individual ADHD medications. It is puzzling that large numbers of specific ADRs are reported in some studies, but few if any in others. These findings question the relevance of the many small clinical trials conducted on the medications, particularly atomoxetine and methylphenidate, as they are not designed to measure long-term efficacy and safety.[@b55-ndt-7-729] Almost all of these clinical trials were sponsored by the pharmaceutical companies producing the subject medications, and therefore, the current reviewers encourage these companies to make information about the ADRs reported in said clinical trials accessible to the public.

Seriousness of reported ADRs
----------------------------

Only a small number of serious ADRs were reported. However, in several of the included studies a large number of children withdrew due to experiencing ADRs, and therefore, the actual number of serious ADRs occurring from the use of ADHD medications might be higher, and some types of ADRs may not have been reported. Information about ADR incidence in the monitored population was only reported if the incidence was above 2% and/or 5%; consequently, information about rarely occurring ADRs is not included. Another issue is that information about definitions and scales to define and evaluate events occurring during the clinical trials is not reported in the articles, thus making it impossible to react to this information. Therefore, the regulatory agencies are encouraged to allow access to the original clinical protocols, so that all information reported for ADHD medications can be made public. A previous study has shown that there are large discrepancies between the data reported in clinical trial protocols and data published in scientific journals.[@b56-ndt-7-729]

Long-term safety aspects of psychostimulant use
-----------------------------------------------

Psychostimulants and other ADHD medications are prescribed for long-term treatment in large populations and there is a need for long-term efficacy and safety studies.[@b1-ndt-7-729] The lack of sufficient knowledge about ADRs at the point of licensing of new medicines makes spontaneous ADR reporting an important source of information about medicine safety.[@b57-ndt-7-729] As clinical trials in the pediatric population are limited, clinicians and health authorities must rely on spontaneous reports as the main source of information about previously unknown ADRs.[@b57-ndt-7-729] However, the current review did not find any studies about ADRs from the use of psychostimulants reported to any national ADR databases. Systematic analyses of ADRs reported to national databases are necessary, as these databases constitute a critical (and underestimated) source of important data, especially information about new, serious, and rarely occurring ADRs. Further studies of data from large databases, ie, the World Health Organization/Uppsala Monitoring Centre VigiBase™ (Uppsala, Sweden) or the European Medicines Agency EudraVigilance (London, United Kingdom \[UK\]) databases, are recommended in order to increase knowledge about ADRs from the use of ADHD medications.

Strengths and limitations of this review
----------------------------------------

The included studies were conducted over a period of approximately 20 years in different countries, with a great deal of inconsistency in observing and classifying the type and seriousness of reported ADRs. Information about the seriousness of the reported ADRs was extracted from the included studies, and it was not possible for the review to evaluate these ratings, nor to estimate ADRs in terms of effect sizes, as the review did not have access to the original data material. A major limitation of this study is that it is unknown to what extent the causality of these ADRs can be confirmed, and this has implications for the interpretation of the findings in the review. A large number of published clinical studies were not included in this review because these articles did not report information about ADRs, despite the fact that pharmaceutical companies had a legal obligation to monitor ADRs in clinical trials, and therefore, these data must exist. As the clinical trials were mainly sponsored by the pharmaceutical companies that produce the medications, these companies are urged to make these data accessible to the public.

Conclusion
==========

Reported ADRs from the use of psychostimulants in the pediatric population were generally found in clinical trials of short duration. Since ADHD medications are prescribed for long-term treatment there is a need for long-term safety studies. Considering the widespread and increasing use of these medications in children, greater care must be taken when prescribing these medications for long-term use. Further studies of spontaneous reports submitted to national and international databases are recommended in order to increase knowledge about ADRs from the use of psychostimulants in the pediatric population. Pharmaceutical companies should make all information about ADRs reported for ADHD medications accessible to the public. Additionally, the impact of the link between researchers and the manufacturers of the medications needs to be studied.
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![Decision tree of the review process.\
**Note:** \*An overview of excluded studies is shown in [Appendix 2](#app2-ndt-7-729){ref-type="app"}.\
**Abbreviation:** ADRs, adverse drug reactions.](ndt-7-729f1){#f1-ndt-7-729}

###### 

Characteristics of included studies by country, design, study population, and funding

  Studies (chronological order)      Country   Design         Setting        Dosage (mg/day)    Comparator    Treatment weeks (N)   Patients included (N)   Patients completed (N)   Age (y)   \% Male   Type of assessor   Funding
  ---------------------------------- --------- -------------- -------------- ------------------ ------------- --------------------- ----------------------- ------------------------ --------- --------- ------------------ -------------
  **Amphetamine**                                                                                                                                                                                                           
  Biederman et al[@b12-ndt-7-729]    USA       R parallel     Naturalistic   30--70             Placebo       4                     290                     218                      6--12     69        Parent             Industry
  Spencer et al[@b13-ndt-7-729]      USA       R parallel     Naturalistic   10--40             Placebo       4                     335                     308                      6--17     69        Parent             Industry
  Wigal et al[@b14-ndt-7-729]        USA       R parallel     Laboratory     10--30             Atomoxetine   3                     102                     93                       6--12     75        Parent             Industry
  Biederman et al[@b15-ndt-7-729]    USA       R parallel     Naturalistic   10--30             Placebo       3                     374                     336                      6--12     80        Parent             Industry
  Efron et al[@b16-ndt-7-729]        AU        R crossover    Naturalistic   0.15 mg/kg         MPH           2                     125                     121                      5--15     91        Teacher/Parent     Nonindustry
                                                                                                                                                                                                                            
  Total/Range                                                                                                 2--4                  1226                    1076                     5--17     69--91                       
                                                                                                                                                                                                                            
  **Methylphenidate**                                                                                                                                                                                                       
  Arabgol et al[@b17-ndt-7-729]      IR        R parallel     Naturalistic   20--50             Reboxetine    6                     16                      12                       7--16     66        Teacher/Parent     Nonindustry
  Maayan et al[@b20-ndt-7-729]       USA       Open label     Naturalistic   10--30             NR            4                     14                      11                       4--5      82        Self               NR
  Amiri et al[@b49-ndt-7-729]        IR        R parallel     Naturalistic   20--30             Modafinil     6                     32                      30                       6--15     80        Teacher/Parent     Nonindustry
  Findling et al[@b18-ndt-7-729]     USA       R parallel     Naturalistic   10--54             Placebo       7                     189                     137                      6--12     65        Self               Industry
  Newcorn et al[@b19-ndt-7-729]      USA       R parallel     Naturalistic   18--54             Atomoxetine   6                     220                     180                      6--16     71        Parent             Industry
  Findling et al[@b21-ndt-7-729]     Various   R parallel     Naturalistic   10--60             Placebo       3                     272                     240                      6--12     80        Self               Industry
  Greenhill et al[@b22-ndt-7-729]    USA       R parallel     Naturalistic   5--30              Placebo       7                     53                      48                       6--17     59        Self               Industry
  McGough et al[@b23-ndt-7-729]      USA       R crossover    Laboratory     10--27             Placebo       5                     42                      41                       6--12     73        Self               Industry
  Gau et al[@b24-ndt-7-729]          TW        R open label   Naturalistic   10--40             None          4                     64                      64                       6--15     91        Self               Industry
  Silva et al[@b25-ndt-7-729]        USA       R crossover    Laboratory     20--40             Placebo       \<1                   54                      53                       6--12     70        Parent             Industry
  Kemner et al[@b26-ndt-7-729]       USA       R open label   Naturalistic   18--72             Atomoxetine   3                     891                     850                      6--12     74        Parent             Industry
  Swanson et al[@b27-ndt-7-729]      USA       R crossover    Laboratory     18--60             Placebo       NR                    184                     181                      6--12     74        Self/Parent        Industry
  Biederman et al[@b28-ndt-7-729]    USA/CA    R parallel     Naturalistic   10--40             Placebo       2                     65                      61                       6--14     80        Parent             Industry
  Kratochvil et al[@b29-ndt-7-729]   USA/CA    R open label   Naturalistic   5--60              None          10                    44                      25                       7--15     100       Parent             Industry
  Pelham et al[@b30-ndt-7-729]       USA       R crossover    Lab/Nat        5--54              Placebo       3                     70                      68                       6--12     NR        Teacher/Parent     Industry
  Efron et al[@b16-ndt-7-729]        AU        R crossover    Naturalistic   0.3 mg/kg          Amphetamine   2                     125                     121                      5--15     91        Teacher/Parent     Nonindustry
                                                                                                                                                                                                                            
  Total/Range                                                                                                 1--10                 2303                    2092                     4--17     59--100                      
                                                                                                                                                                                                                            
  **Atomoxetine**                                                                                                                                                                                                           
  Svanborg et al[@b31-ndt-7-729]     SE        R parallel     Naturalistic   80                 Placebo       10                    49                      49                       7--15     80        Self               Industry
  Block et al[@b32-ndt-7-729]        USA       R parallel     Naturalistic   0.47--1.81 mg/kg   Placebo       6                     288                     140                      6--12     73        Parent             Industry
  Tamayo et al[@b33-ndt-7-729]       Various   Open label     Naturalistic   35--120            None          10--11                1198                    947                      6--17     76        Self               Industry
  Newcorn et al[@b19-ndt-7-729]      USA       R parallel     Naturalistic   0.8--1.8 mg/kg     MPH/Placebo   6                     222                     186                      6--16     78        Parent             Industry
  Bangs et al[@b34-ndt-7-729]        US        R parallel     Naturalistic   1.2--1.8 mg/kg     Placebo       9                     72                      71                       12--17    72        Self               Industry
  Geller et al[@b35-ndt-7-729]       USA       R parallel     Naturalistic   0.8--1.8 mg/kg     Placebo       12                    87                      66                       8--17     62        Self               Industry
  Gau et al[@b36-ndt-7-729]          TW        R parallel     Naturalistic   16--99             Placebo       6                     72                      72                       6--16     90        Parent             Industry
  Kratochvil et al[@b37-ndt-7-729]   USA       Open label     Naturalistic   0.5--1.8 mg/kg     None          8                     22                      20                       5--6      86        Parent             Industry
  Prasad et al[@b38-ndt-7-729]       UK        R open label   Naturalistic   0.5--1.8 mg/kg     SCT           10                    104                     78                       7--15     89        Self               Industry
  Arnold et al[@b39-ndt-7-729]       USA       R cross over   Naturalistic   2.5--40            Placebo       12                    16                      15                       5--15     75        Self               Industry
  Newcorn et al[@b40-ndt-7-729]      USA       R parallel     Naturalistic   1.2--1.8 mg/kg     None          32                    229                     160                      6--16     72        Parent             Industry
  Wigal et al[@b14-ndt-7-729]        USA       R parallel     Laboratory     10--60             Amphetamine   3                     101                     97                       6--12     76        Parent             Industry
  Allen et al[@b42-ndt-7-729]        USA       R parallel     Naturalistic   0.5--1.5 mg/kg     Placebo       18                    76                      74                       7--17     92        Self               Industry
  Kemner et al[@b26-ndt-7-729]       USA       R open label   Naturalistic   10--80             MPH           3                     499                     473                      6--12     74        Parent             Industry
  Escobar et al[@b41-ndt-7-729]      ES        Open label     Naturalistic   0.5--1.8 mg/kg     None          10                    36                      36                       6--15     89        Parent             Industry
  Kelsey et al[@b43-ndt-7-729]       USA       R parallel     Naturalistic   0.8--1.2 mg/kg     Placebo       8                     133                     107                      6--12     71        Parent             Industry
  Biederman et al[@b44-ndt-7-729]    USA       R parallel     Naturalistic   2 mg/kg            Placebo       9                     31                      31                       7--13     0         Self               Industry
  Michelson et al[@b45-ndt-7-729]    USA       R parallel     Naturalistic   0.5--1.0 mg/kg     Placebo       6                     85                      84                       6--16     71        Parent             Industry
  Kratochvil et al[@b29-ndt-7-729]   USA/CA    R open label   Naturalistic   0.2--2.0 mg/kg     None          10                    184                     118                      7--15     91        Parent             Industry
  Spencer et al[@b46-ndt-7-729]      USA       R parallel     Naturalistic   90                 Placebo       12                    129                     127                      7--13     76        Parent             Industry
  Michelson et al[@b47-ndt-7-729]    USA       R parallel     Naturalistic   0.5--1.8 mg/kg     Placebo       8                     213                     176                      8--17     71        Self               Industry
                                                                                                                                                                                                                            
  Total/Range                                                                                                 3--32                 3846                    3127                     5--17     0--91                        
                                                                                                                                                                                                                            
  **Modafinil**                                                                                                                                                                                                             
  Kahbazi et al[@b48-ndt-7-729]      IR        R parallel     Naturalistic   200--300           Placebo       6                     24                      23                       6--15     76        Teacher/Parent     Nonindustry
  Amiri et al[@b49-ndt-7-729]        IR        R parallel     Naturalistic   200--300           MPH           6                     32                      30                       6--15     78        Teacher/Parent     Nonindustry
  Boellner et al[@b50-ndt-7-729]     USA       Open label     Naturalistic   100--400           None          8                     220                     166                      6--14     72        Parent             Industry
  Wigal et al[@b51-ndt-7-729]        USA       R parallel     Naturalistic   170--425           Placebo       9                     423                     411                      10.2      72        Parent/Self        Industry
  Biederman et al[@b52-ndt-7-729]    USA       R parallel     Naturalistic   300--400           Placebo       4                     197                     175                      6--14     75        Parent             Industry
  Greenhill et al[@b53-ndt-7-729]    USA       R parallel     Naturalistic   170--425           Placebo       9                     133                     100                      6--16     73        Parent/Self        Industry
  Biederman et al[@b54-ndt-7-729]    USA       R parallel     Naturalistic   170--425           Placebo       9                     164                     97                       6--17     69        Parent             Industry
                                                                                                                                                                                                                            
  Total/Range                                                                                                 4--9                  1137                    949                      6--17     69--75                       
                                                                                                                                                                                                                            
  Total all studies                                                                                                                 8512                    7244                     --        --                           

**Abbreviations:** AU, Australia; CA, Canada; IR, Iran; lab, laboratory; MPH, methylphenidate; nat, naturalistic; NR, not reported; R, randomized; ES, Spain; SCT, standard current therapy; SE, Sweden; TW, Taiwan; USA, United States of America.

###### 

Adverse drug reaction reporting rates (%) for amphetamine derivates by category and study

  Reference number            [@b12-ndt-7-729]   [@b13-ndt-7-729]   [@b14-ndt-7-729]   [@b15-ndt-7-729]   [@b16-ndt-7-729]   Range    Placebo (range)
  --------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ -------- -----------------
  **Adverse drug reaction**                                                                                                           
  Accidental injury           --                 5                  --                 --                 --                 5        5
  Anorexia                    --                 25                 17                 22                 --                 17--25   2
  Anxiety                     --                 --                 --                 --                 68                 68       --
  Appetite decrease           39                 --                 28                 --                 59                 28--59   4--5
  Cough                       1                  --                 --                 5                  --                 1--5     5
  Crying                      --                 --                 --                 --                 76                 76       --
  Daydreams                   --                 --                 --                 --                 62                 62       --
  Dizziness                   5                  --                 6                  --                 32                 5--32    --
  Dry mouth                   5                  --                 --                 --                 --                 5        --
  Emotional disturbance       --                 --                 --                 --                 59                 59       --
  Emotional lability          --                 5                  --                 9                  --                 5--9     2
  Fatigue                     --                 --                 2                  --                 --                 2        --
  Fingernail biting           --                 --                 --                 --                 40                 40       --
  Gastrointestinal pain       12                 11                 19                 14                 --                 11--19   5--10
  Headache                    12                 19                 15                 18                 30                 12--30   10--21
  Insomnia                    19                 20                 28                 17                 --                 17--28   2--8
  Irritability                10                 --                 7                  --                 82                 7--82    --
  Nasal congestion            1                  --                 --                 --                 --                 1        --
  Nasopharyngitis             5                  --                 --                 --                 --                 5        --
  Nausea                      6                  --                 7                  5                  --                 5--7     3
  Nervousness                 --                 6                  --                 6                  --                 6        2
  Nightmares                  --                 --                 --                 --                 28                 28       --
  Pharyngitis                 --                 7                  --                 7                  --                 7        5--20
  Sleeping problems           --                 --                 --                 --                 70                 70       --
  Social withdrawal           --                 --                 --                 --                 64                 64       --
  Somnolence                  --                 --                 5                  --                 --                 5        --
  Stomachache                 --                 --                 --                 --                 40                 40       --
  Tics                        --                 --                 --                 --                 26                 26       --
  Unusually happy             --                 --                 --                 --                 26                 26       --
  Vomiting                    9                  --                 5                  7                  --                 5--9     4
  Weight changes              9                  8                  6                  --                 --                 6--9     1

###### 

Adverse drug reaction reporting rates (%) for methylphendiate by category and study

  Reference number              [@b16-ndt-7-729]   [@b17-ndt-7-729]   [@b18-ndt-7-729]   [@b19-ndt-7-729]   [@b20-ndt-7-729]   [@b21-ndt-7-729]   [@b22-ndt-7-729]   [@b23-ndt-7-729]   [@b24-ndt-7-729]   [@b25-ndt-7-729]   [@b26-ndt-7-729]   [@b27-ndt-7-729]   [@b28-ndt-7-729]   [@b29-ndt-7-729]   [@b30-ndt-7-729]   [@b49-ndt-7-729]   Range    Placebo (range)
  ----------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ -------- -----------------
  **Adverse drug reaction**                                                                                                                                                                                                                                                                                                                              
  Abnormal behavior             --                 --                 --                 --                 --                 3                  --                 --                 --                 --                 1                  --                 --                 5                  --                 --                 1--5     4
  Accidental injury             --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 3                  --                 13                 3                  --                 3--13    3
  Affect lability               --                 --                 3                  --                 --                 --                 4                  --                 --                 --                 --                 --                 --                 --                 --                 --                 3--4     --
  Aggression                    --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 1                  --                 --                 --                 --                 --                 1        --
  Anorexia                      --                 --                 3                  --                 --                 5                  4                  3                  --                 8                  --                 3                  3                  15                 --                 --                 3--15    1--2
  Anxiety                       61                 --                 --                 --                 --                 --                 --                 --                 25                 --                 --                 --                 --                 --                 --                 5                  5--61    1
  Appetite decrease             56                 31                 19                 17                 28                 3                  30                 --                 53                 9                  6                  3                  --                 --                 --                 31                 3--56    5--9
  Asthenia                      --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 3                  --                 --                 3        --
  Blood pressure changes        --                 --                 --                 18                 --                 --                 --                 3                  --                 --                 --                 --                 --                 --                 --                 --                 3--18    --
  Changes in heart rate         --                 --                 --                 12                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 12       --
  Changes in pulse rate         --                 --                 --                 --                 --                 --                 --                 --                 --                 1                  --                 --                 --                 --                 --                 --                 1        --
  Chest pain                    --                 6                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 6        --
  Cough                         --                 --                 --                 4                  --                 2                  --                 --                 --                 --                 --                 --                 --                 5                  --                 --                 2--5     4
  Crying                        71                 --                 --                 --                 --                 --                 --                 --                 38                 --                 2                  --                 --                 --                 --                 --                 2--71    --
  Daydreams                     62                 --                 --                 --                 --                 --                 --                 --                 30                 --                 --                 --                 --                 --                 --                 --                 30--62   --
  Depression                    --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 --                 5        --
  Diarrhea                      --                 --                 --                 --                 --                 --                 4                  --                 --                 --                 --                 --                 --                 3                  2                  --                 2--4     1--2
  Dizziness                     30                 13                 --                 --                 --                 --                 --                 --                 13                 --                 1                  --                 --                 --                 2                  --                 1--30    4
  Dry mouth                     --                 --                 --                 --                 --                 --                 --                 --                 24                 --                 --                 --                 --                 --                 --                 12                 12--24   --
  Dyspepsia                     --                 --                 --                 --                 --                 --                 8                  --                 --                 --                 --                 --                 --                 5                  --                 --                 5--8     --
  Emotional disturbance         56                 --                 --                 --                 --                 --                 --                 --                 --                 --                 1                  --                 --                 --                 --                 --                 1--56    --
  Emotional lability            --                 --                 --                 --                 8                  --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 7                  5--8     --
  Euphoria                      --                 --                 --                 --                 --                 --                 --                 --                 9                  --                 --                 --                 --                 --                 --                 --                 9        --
  Eye redness                   --                 --                 --                 --                 4                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 4        --
  Eye twitching                 --                 --                 --                 --                 4                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 4        --
  Fatigue                       --                 --                 --                 2                  4                  --                 4                  --                 --                 4                  1                  --                 --                 --                 --                 --                 1--4     4
  Fever                         --                 --                 --                 --                 4                  2                  --                 --                 --                 --                 --                 --                 --                 10                 --                 --                 2--10    7
  Fingerrnail biting            45                 --                 --                 --                 --                 --                 --                 --                 22                 --                 --                 --                 --                 --                 --                 --                 22--45   --
  Gastroenteritis               --                 --                 --                 --                 --                 --                 4                  --                 --                 --                 --                 5                  --                 --                 --                 --                 4--5     4
  Gastrointestinal pain         --                 --                 --                 10                 12                 10                 19                 --                 --                 6                  4                  4                  --                 18                 15                 8                  4--19    2--13
  Headache                      24                 --                 --                 11                 4                  16                 25                 4                  28                 2                  4                  3                  2                  33                 14                 8                  2--33    3--23
  Hyperkinesia                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 --                 5        --
  Increases in ALT/AST          --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 --                 --                 --                 5        --
  Infection                     --                 --                 --                 --                 4                  --                 --                 --                 --                 --                 --                 2                  --                 8                  --                 --                 2--8     1--4
  Influenza                     --                 --                 --                 --                 --                 --                 4                  --                 --                 --                 --                 --                 --                 10                 --                 --                 4--10    --
  Insomnia                      --                 19                 8                  27                 --                 4                  8                  --                 44                 4                  7                  2                  3                  18                 --                 --                 2--44    3--10
  Irritability                  80                 6                  --                 6                  4                  3                  4                  --                 16                 --                 1                  1                  --                 --                 --                 7                  1--80    2--6
  Lymphadenopathy               --                 --                 --                 --                 --                 --                 --                 3                  --                 --                 --                 --                 --                 --                 --                 --                 3        --
  Mood alteration               --                 --                 --                 --                 --                 --                 --                 --                 34                 --                 1                  7                  --                 --                 --                 --                 1--34    --
  Nasal congestion              --                 --                 3                  --                 4                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 3--4     1
  Nasopharyngitis               --                 --                 4                  --                 --                 4                  9                  1                  --                 --                 --                 --                 --                 --                 --                 --                 1--9     2--7
  Nausea                        --                 --                 8                  6                  --                 --                 11                 4                  --                 --                 1                  --                 --                 5                  --                 5                  1--11    2--6
  Nervousness                   --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 4                  --                 10                 --                 --                 4--10    --
  Nightmare                     21                 --                 --                 --                 --                 --                 --                 --                 16                 --                 --                 --                 --                 --                 --                 --                 16--21   --
  Otitis media                  --                 --                 --                 --                 --                 --                 4                  --                 --                 --                 --                 --                 --                 --                 --                 --                 4        2
  Pain                          --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 3                  --                 --                 3        --
  Pallor                        --                 13                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 13       --
  Palpitation                   --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 --                 5        --
  Pharyngeal pain               --                 --                 --                 --                 --                 --                 --                 3                  --                 --                 --                 --                 --                 --                 --                 --                 3        --
  Pharyngitis                   --                 --                 --                 --                 --                 3                  --                 --                 --                 --                 --                 --                 --                 8                  2                  --                 2--8     3
  Rash                          --                 --                 --                 --                 --                 --                 --                 1                  --                 --                 --                 --                 --                 8                  --                 --                 1--8     4
  Respiratory tract infection   --                 --                 --                 --                 --                 3                  9                  --                 --                 --                 --                 --                 --                 --                 4                  --                 3--9     2--6
  Rhinitis                      --                 --                 --                 --                 --                 --                 --                 3                  --                 --                 --                 --                 --                 20                 2                  --                 2--20    --
  Sensitivity                   --                 --                 --                 --                 4                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 4        --
  Sleeping problems             64                 --                 --                 --                 12                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 9                  9--64    --
  Socially withdrawn            59                 --                 --                 --                 --                 --                 --                 --                 27                 --                 --                 --                 --                 --                 --                 --                 27--59   --
  Somnolence                    --                 --                 --                 2                  --                 --                 --                 --                 --                 --                 1                  --                 --                 --                 --                 --                 1--2     --
  Stomachache                   32                 --                 --                 --                 --                 --                 4                  --                 28                 --                 --                 --                 --                 --                 --                 --                 4--32    --
  Tachycardia                   --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 --                 5        --
  Tics                          28                 --                 1                  --                 --                 --                 --                 --                 13                 --                 --                 --                 --                 --                 --                 --                 1--28    4
  Twitching                     --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 3                  --                 3        --
  Unusually happy               28                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 28       --
  Urinary incontinence          --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 1                  --                 1        3
  Vomiting                      --                 --                 10                 4                  4                  3                  4                  --                 --                 --                 1                  1                  --                 --                 3                  --                 1--10    2--5
  Weight changes                --                 --                 8                  1                  --                 --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 8                  1--8     4

**Abbreviation:** AST/ALT, aspartate aminotransferase/alanine aminotransferase.

###### 

Adverse drug reaction reporting rates (%) for atomoxetine by category and study

  Reference number              [@b14-ndt-7-729]   [@b19-ndt-7-729]   [@b26-ndt-7-729]   [@b29-ndt-7-729]   [@b31-ndt-7-729]   [@b32-ndt-7-729]   [@b33-ndt-7-729]   [@b34-ndt-7-729]   [@b35-ndt-7-729]   [@b36-ndt-7-729]   [@b37-ndt-7-729]   [@b38-ndt-7-729]   [@b39-ndt-7-729]   [@b40-ndt-7-729]   [@b41-ndt-7-729]   [@b42-ndt-7-729]   [@b43-ndt-7-729]   [@b44-ndt-7-729]   [@b45-ndt-7-729]   [@b46-ndt-7-729]   [@b47-ndt-7-729]   Range    Placebo (range)
  ----------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ -------- -----------------
  **Adverse drug reaction**                                                                                                                                                                                                                                                                                                                                                                                                                             
  Abnormal behavior             --                 --                 2                  --                 --                 --                 --                 --                 --                 --                 19                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 2--19    --
  Accidental injury             --                 --                 --                 5                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 6                  --                 3                  3--6     5--8
  Aggression                    --                 --                 1                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 1        --
  Anorexia                      9                  --                 --                 19                 35                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 9--35    5
  Appetite decrease             18                 14                 3                  --                 6                  11                 10                 13                 14                 36                 50                 8                  38                 15                 31                 16                 18                 19                 20                 22                 --                 3--50    3--25
  Asthenia                      --                 --                 --                 8                  --                 --                 --                 --                 --                 10                 --                 --                 --                 --                 --                 --                 --                 --                 11                 --                 5                  5--11    1--5
  Blunted effect                --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5        --
  Blood pressure changes        --                 18                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 18       16
  Changes in heart rate         --                 11                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 19                 --                 --                 --                 --                 --                 --                 --                 --                 11--19   12
  Constipation                  --                 --                 --                 --                 --                 --                 4                  --                 --                 --                 --                 --                 6                  --                 --                 --                 --                 --                 --                 --                 --                 4--6     6
  Cough                         --                 3                  --                 5                  --                 --                 7                  --                 5                  13                 --                 6                  --                 5                  --                 5                  --                 16                 7                  13                 10                 3--16    5--21
  Crying                        --                 --                 1                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 1        --
  Depression                    --                 --                 --                 3                  10                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 3--10    4--6
  Diarrhea                      --                 --                 --                 7                  --                 --                 --                 1                  --                 6                  5                  --                 6                  --                 --                 4                  2                  3                  --                 --                 5                  1--7     5--13
  Dilated pupils                --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5        --
  Dizziness                     2                  --                 2                  --                 --                 --                 6                  13                 --                 10                 --                 --                 --                 --                 --                 --                 --                 3                  6                  --                 5                  2--13    1--5
  Dry mouth                     --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 6                  --                 --                 --                 --                 --                 --                 --                 --                 6        6
  Dyspepsia                     --                 --                 --                 5                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 6                  --                 9                  --                 --                 5--9     --
  Emotional disturbance         --                 --                 1                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 1        --
  Emotional lability            --                 --                 --                 6                  --                 --                 --                 --                 --                 --                 55                 --                 --                 8                  --                 --                 --                 3                  7                  --                 --                 3--55    5--14
  Fatigue                       7                  5                  3                  --                 33                 --                 4                  13                 --                 --                 5                  --                 --                 5                  --                 12                 10                 --                 --                 --                 --                 3--33    1--18
  Fever/pyrexia                 --                 --                 --                 11                 4                  --                 5                  3                  --                 4                  --                 --                 --                 10                 --                 --                 --                 10                 7                  --                 5                  3--11    4--15
  Gastroenteritis               --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 31                 --                 --                 --                 --                 --                 --                 --                 --                 31       --
  Gastrointestinal pain         15                 11                 5                  23                 47                 13                 7                  8                  12                 8                  27                 7                  --                 12                 --                 9                  15                 29                 17                 31                 13                 5--47    4--22
  Headache                      10                 18                 4                  31                 39                 9                  17                 17                 14                 10                 14                 21                 13                 21                 17                 21                 7                  26                 20                 30                 24                 4--39    4--28
  Hyperkinesia                  --                 --                 --                 2                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 2        --
  Infection                     --                 --                 --                 4                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 4                  4        1
  Influenza                     --                 --                 --                 5                  --                 --                 --                 4                  5                  --                 --                 --                 --                 5                  --                 --                 --                 --                 --                 --                 --                 4--5     1--6
  Insomnia                      7                  7                  3                  9                  --                 --                 5                  --                 --                 11                 --                 --                 19                 --                 --                 --                 --                 3                  --                 --                 7                  3--19    1--13
  Irritability                  4                  6                  2                  --                 12                 --                 --                 6                  7                  --                 --                 --                 --                 10                 --                 --                 --                 --                 --                 --                 --                 2--12    1--4
  Mood alteration               --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 44                 --                 --                 --                 --                 --                 --                 --                 --                 44       31
  Nasal congestion              --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 6                  --                 --                 --                 --                 --                 --                 --                 6        --
  Nasopharyngitis               --                 --                 --                 --                 --                 4                  5                  --                 7                  --                 --                 --                 --                 14                 --                 --                 --                 --                 --                 --                 --                 4--14    6--8
  Nausea                        9                  4                  5                  10                 29                 6                  9                  22                 7                  17                 5                  17                 31                 5                  --                 16                 12                 7                  12                 10                 6                  4--31    1--14
  Nervousness                   --                 --                 --                 16                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 7                  --                 13                 6                  6--16    5--7
  Oppositional behavior         --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 11                 --                 --                 --                 --                 --                 --                 11       --
  Pain                          --                 --                 --                 5                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 6                  5--6     6
  Palpitation                   --                 --                 --                 2                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 2        --
  Pharyngeal pain               --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 10                 --                 --                 --                 --                 --                 --                 --                 10       --
  Pharyngitis                   --                 --                 --                 6                  --                 --                 --                 --                 --                 7                  --                 --                 --                 5                  17                 4                  --                 19                 7                  16                 10                 4--19    9--19
  Pruritus                      --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 4                  4        --
  Rash                          --                 --                 --                 4                  --                 --                 --                 --                 --                 --                 --                 --                 13                 --                 --                 --                 --                 --                 7                  --                 7                  4--13    4--6
  Respiratory tract infection   --                 --                 --                 --                 10                 3                  --                 --                 --                 --                 --                 --                 --                 8                  --                 --                 --                 --                 --                 --                 --                 3--10    4
  Restlessness                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 13                 --                 --                 --                 --                 --                 --                 --                 --                 13       19--21
  Rhinitis                      --                 --                 --                 18                 --                 --                 --                 --                 --                 8                  --                 --                 --                 --                 --                 --                 --                 26                 17                 26                 14                 8--26    15--38
  Sinusitis                     --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5        4
  Somnolence                    19                 6                  4                  11                 --                 8                  --                 --                 --                 22                 36                 --                 --                 5                  --                 --                 15                 7                  11                 9                  8                  4--36    1--14
  Stomachache                   --                 --                 --                 --                 --                 5                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5        --
  Tachycardia                   --                 --                 --                 6                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 14                 --                 --                 --                 --                 --                 --                 6--14    --
  Thirst                        --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 14                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 14       --
  Throat pain                   --                 --                 --                 --                 --                 --                 3                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 3        --
  Tics                          --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5                  --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 5        7
  Tired                         --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 --                 31                 --                 --                 --                 --                 --                 --                 --                 --                 31       4--13
  Vomiting                      13                 7                  2                  12                 12                 12                 7                  13                 10                 7                  14                 9                  --                 8                  11                 16                 6                  19                 15                 15                 8                  2--19    1--12
  Weight changes                4                  1                  --                 3                  --                 --                 --                 9                  --                 6                  --                 8                  --                 --                 --                 --                 --                 --                 --                 --                 --                 1--9     1--6

###### 

Adverse drug reaction reporting rates (%) for modafinil by category and study

  Reference number              [@b48-ndt-7-729]   [@b49-ndt-7-729]   [@b50-ndt-7-729]   [@b51-ndt-7-729]   [@b52-ndt-7-729]   [@b53-ndt-7-729]   [@b54-ndt-7-729]   Range    Placebo (range)
  ----------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ -------- -----------------
  **Adverse drug reaction**                                                                                                                                                   
  Abnormal behavior             --                 --                 --                 --                 --                 --                 --                 --       4
  Accidental injury             --                 --                 5                  --                 --                 5                  5                  5        3--6
  Anorexia                      --                 --                 --                 --                 --                 --                 --                 --       1--2
  Anxiety                       --                 --                 --                 --                 --                 --                 --                 --       1--12
  Appetite decrease             35                 25                 6                  16                 7                  18                 16                 6--35    2--12
  Asthenia                      --                 --                 --                 --                 --                 --                 4                  4        5
  Cough                         --                 --                 5                  8                  7                  9                  8                  5--9     4--9
  Diarrhea                      --                 --                 --                 --                 --                 --                 --                 --       1--2
  Dry mouth                     14                 14                 --                 --                 --                 --                 --                 14       18
  Dyspepsia                     --                 --                 --                 --                 --                 --                 --                 --       4
  Emotional disturbance         --                 --                 --                 --                 --                 --                 --                 --       12
  Emotional lability            8                  4                  5                  --                 --                 5                  --                 5--8     2--6
  Fatigue                       --                 --                 --                 --                 --                 --                 --                 --       4
  Fever                         --                 --                 --                 5                  6                  5                  5                  5--6     2--7
  Gastroenteritis               --                 --                 --                 --                 --                 5                  --                 5        4
  Gastrointestinal pain         8                  7                  --                 10                 9                  12                 7                  7--12    2--13
  Headache                      8                  7                  10                 20                 13                 22                 20                 7--22    3--23
  Infection                     --                 --                 5                  11                 6                  11                 12                 5--12    1--15
  Influenza                     --                 --                 --                 --                 --                 --                 --                 --       9
  Insomnia                      --                 --                 13                 27                 12                 28                 29                 12--29   2--10
  Irritability                  8                  7                  --                 --                 --                 --                 --                 7--8     2--6
  Nasal congestion              --                 --                 --                 --                 --                 --                 --                 --       1
  Nasopharyngitis               --                 --                 --                 --                 --                 --                 --                 --       2--7
  Nausea                        4                  7                  --                 --                 --                 5                  --                 4--7     2--12
  Nervousness                   6                  7                  --                 5                  --                 5                  4                  4--7     2--6
  Otitis media                  --                 --                 --                 --                 --                 --                 --                 --       2
  Pain                          --                 --                 --                 --                 --                 --                 5                  5        1
  Pharyngeal pain               --                 --                 --                 --                 --                 --                 --                 --       1--7
  Pharyngitis                   --                 --                 --                 7                  --                 8                  9                  7--9     3--13
  Rash                          --                 --                 --                 --                 --                 --                 6                  6        4
  Respiratory tract infection                                                                                                                                                 2--6
  Rhinitis                      --                 --                 5                  7                  5                  8                  10                 5--10    4--11
  Sleeping problems             4                  14                 --                 --                 --                 --                 --                 4--14    12
  Somnolence                    --                 --                 --                 --                 --                 5                  2                  2--5     4--5
  Tics                          --                 --                 --                 --                 --                 --                 --                 --       4
  Urinary incontinence          --                 --                 --                 --                 --                 --                 --                 --       3
  Vomiting                      --                 --                 --                 5                  --                 6                  6                  5--6     2--9
  Weight changes                6                  7                  --                 --                 --                 5                  --                 5--7     1--6

###### 

Serious ADRs reported for ADHD medications in identified studies

  Medication (alphabetically)   Reference                          Adverse drug reaction(s)
  ----------------------------- ---------------------------------- ---------------------------
  Amphetamine                   Spencer et al[@b13-ndt-7-729]      Arthrosis
                                                                   Hyperkinesia
                                                                   Insomnia
                                                                   Nervousness
                                                                   Pharyngitis
                                                                   Suicide attempt
                                Wigal et al[@b14-ndt-7-729]        Emotional disturbance
                                                                   Headache
                                Biedermann et al[@b15-ndt-7-729]   Anorexia
                                                                   Emotional lability
                                                                   Insomnia
                                Efron et al[@b16-ndt-7-729]        Agitation
                                                                   Aggression
                                                                   Anxiety
  Methylphenidate               Efron et al[@b16-ndt-7-729]        Aggression
                                                                   Headache
                                                                   Tearful
                                Greenhill et al[@b22-ndt-7-729]    Hypersomnia
                                Kemner et al[@b26-ndt-7-729]       Mania
                                Biederman et al[@b28-ndt-7-729]    Depression
  Atomoxetine                   Wigal et al[@b14-ndt-7-729]        Upper abdominal pain
                                Arnold et al[@b39-ndt-7-729]       Aggression
  Modafinil                     Boellner et al[@b50-ndt-7-729]     Insomnia
                                Biederman et al[@b52-ndt-7-729]    Insomnia
                                Wigal et al[@b51-ndt-7-729]        Asthma
                                                                   Dehydration
                                                                   Duodenitis
                                                                   Erythema multiforme
                                                                   Hypertonia
                                                                   Influenza syndrome
                                                                   Peptic ulcer
                                                                   Stevens--Johnson syndrome

**Abbreviations:** ADRs, adverse drug reactions; ADHD, attention deficit hyperactivity disorder.
